logo-loader
RNS
Trellus Health PLC

Trellus Health PLC - AGM Statement

RNS Number : 8593O
Trellus Health PLC
30 June 2025
 

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

AGM Statement

 

LONDON, U.K. AND NEW YORK, U.S. (30 June 2025). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it will hold its Annual General Meeting at 1.00pm (BST) today at the Company's registered office, 201 Temple Chambers, 3-7 Temple Avenue, London, United Kingdom, EC4Y 0DT.

 

Kevin L. Murphy Jr., Chairman will address the meeting with the following update:

 

"We continue to focus on Trellus Health's key commercial verticals: pharmaceutical patient support programs, clinical trial patient recruitment and retention services, and the U.S. health plan sector. Notably, Trellus Health has recently been granted preferred vendor status by a leading global contract research organisation (CRO), and whilst not revenue generating in itself, this reinforces the value of our proprietary resilience methodology.

 

"Our collaborative relationship with Johnson & Johnson remains strong and we are already delivering on key early metrics of patient satisfaction ratings and engagement.

 

"We have continued to maintain strong discipline in our cash management and have further reduced our cost base from the average monthly burn of $500k, year to date, as announced at our annual results. With effect from August 1 2025, our average monthly cash burn will be reduced to $440k per month. This has been a focus of the Group, even as we expand our go-to-market strategy within the pharmaceutical sector. These additional reductions have extended the cash runway into mid-November 2025. The Company continues to evaluate all commercial options, including ongoing discussions with a number of potential commercial partners and discussions with professional advisers in relation to fund raising options."

 

Enquiries:

 

Trellus Health plc

 https://trellushealth.com/

 

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder

Via Walbrook PR

Joy Bessenger, Chief Financial Officer




Singer Capital Markets

 

Jen Boorer / James Todd / Jalini Kalaravy

Tel: +44 (0)20 7496 3000



Walbrook PR

Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com

Paul McManus / Lianne Applegarth /

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/

Alice Woodings

 

+44 (0)7407 804 654

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMUKUSRVSUNUAR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read